The management of sickle cell pain
- Robert E. Richard
- … show all 1 hide
Purchase on Springer.com
$39.95 / €34.95 / £29.95*
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.
Treatment of pain in the setting of sickle cell disease remains unsatisfactory. The approach remains to treat the pain symptomatically with escalating doses of non-opioid and opioid medications while any underlying inciting process is investigated. For the majority of patients with sickle cell disease, pain will always be part of their lives. Advances in the treatment of sickle cell pain will depend on multiple approaches, including both pharmacologic and nonpharmacologic.
- Shapiro BS, Benjamin LJ, Payne R, Heidrich G: Sickle cell-related pain: perceptions of medical practitioners. J Pain Symptom Manage 1997, 14:168–174. CrossRef
- Wright K, Adeosum O: Barriers to effective pain management in sickle cell disease. Br J Nurs 2009, 18:158–161.
- Platt OS: Hydroxyurea for the treatment of sickle cell anemia. N Engl J Med 2008, 358:1362–1369. CrossRef
- Platt OS, Thorington BD, Brambilla DJ, et al.: Pain in sickle cell disease. Rates and risk factors. N Engl J Med 1991, 325:11–16.
- Alexander N, Higgs D, Dover G, Serjeant GR: Are there clinical phenotypes of homozygous sickle cell disease? Br J Haematol 2004, 126:606–611. CrossRef
- Smith WR, Penberthy LT, Bovbjerg VE, et al.: Daily assessment of pain in adults with sickle cell disease. Ann Intern Med 2008, 148:94–101.
- Bunn HF: Pathogenesis and treatment of sickle cell disease. N Engl J Med 1997, 337:762–769. CrossRef
- Turhan A, Weiss LA, Mohandas N, et al.: Primary role for adherent leukocytes in sickle cell vascular occlusion: a new paradigm. Proc Natl Acad Sci U S A 2002, 99:3047–3051. CrossRef
- Kato GJ, Gladwin MT, Steinberg MH: Deconstructing sickle cell disease: reappraisal of the role of hemolysis in the development of clinical subphenotypes. Blood Rev 2007, 21:37–47. CrossRef
- Kato GJ, Gladwin MT: Evolution of novel small-molecule therapeutics targeting sickle cell vasculopathy. JAMA 2008, 300:2638–2646. CrossRef
- Morrissey LK, Shea JO, Kalish LA, et al.: Clinical practice guideline improves the treatment of sickle cell disease vasoocclusive pain. Pediatr Blood Cancer 2009, 52:369–372. CrossRef
- Melzer-Lange MD, Walsh-Kelly CM, Lea G, et al.: Patient-controlled analgesia for sickle cell pain crisis in a pediatric emergency department. Pediatr Emerg Care 2004, 20:2–4. CrossRef
- van Beers EJ, van Tuijn CF, Nieuwkerk PT, et al.: Patient-controlled analgesia versus continuous infusion of morphine during vaso-occlusive crisis in sickle cell disease, a randomized controlled trial. Am J Hematol 2007, 82:955–960. CrossRef
- Setty BN, Rao AK, Stuart MJ: Thrombophilia in sickle cell disease: the red cell connection. Blood 2001, 98:3228–3233. CrossRef
- Austin H, Key NS, Benson JM, et al.: Sickle cell trait and the risk of venous thromboembolism among blacks. Blood 2007, 110:908–912. CrossRef
- Charache S, Terrin ML, Moore RD, et al.: Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. N Engl J Med 1995, 332:1317–1322. CrossRef
- Steinberg MH, Barton F, Castro O, et al.: Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment. JAMA 2003, 289:1645–1651. CrossRef
- Kinney TR, Helms RW, O’Branski EE, et al.: Safety of hydroxyurea in children with sickle cell anemia: results of the HUG-KIDS study, a phase I/II trial. Pediatric Hydroxyurea Group. Blood 1999, 94:1550–1554.
- Zimmerman SA, Schultz WH, Burgett S, et al.: Hydroxyurea therapy lowers transcranial Doppler flow velocities in children with sickle cell anemia. Blood 2007, 110:1043–1047. CrossRef
- Brawley OW, Cornelius LJ, Edwards LR, et al.: National Institutes of Health Consensus Development Conference statement: hydroxyurea treatment for sickle cell disease. Ann Intern Med 2008, 148:932–938.
- Vichinsky EP, Neumayr LD, Earles AN, et al.: Causes and outcomes of the acute chest syndrome in sickle cell disease. National Acute Chest Syndrome Study Group. N Engl J Med 2000, 342:1855–1865. CrossRef
- Barakat LP, Patterson CA, Daniel LC, Dampier C: Quality of life among adolescents with sickle cell disease: mediation of pain by internalizing symptoms and parenting stress. Health Qual Life Outcomes 2008, 6:60. CrossRef
- Pence L, Valrie CR, Gil KM, et al.: Optimism predicting daily pain medication use in adolescents with sickle cell disease. J Pain Symptom Manage 2007, 33:302–309. CrossRef
- Angst MS, Clark JD: Opioid-induced hyperalgesia: a qualitative systematic review. Anesthesiology 2006, 104:570–587. CrossRef
- Benjamin L: Pain management in sickle cell disease: palliative care begins at birth? Hematology Am Soc Hematol Educ Program 2008, 2008:466–474.
- The management of sickle cell pain
Current Pain and Headache Reports
Volume 13, Issue 4 , pp 295-297
- Cover Date
- Print ISSN
- Online ISSN
- Current Science Inc.
- Additional Links
- Author Affiliations
- 1. Seattle Cancer Care Alliance, Adult Sickle Cell Clinic, Puget Sound Health Care System, Division of Hematology, University of Washington School of Medicine, 1600 South Columbian Way, S-111-Hem, Seattle, WA, 98108, USA